The significant upregulation of MYB in TNBC cells suggests its potential as a therapeutic target, consistent with observations in adenoid cystic carcinoma (ACC), where MYB inhibition via peptidomimetics suppresses tumor growth [38]. Here, MYB is linked to adenoid cystic carcinoma.